MGI Pharma MOGN New patents, anti cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: sim1 who wrote (1178)	3/25/1999 7:46:00 PM
From: scaram(o)uche	Read Replies (1) of 1826

Stuart: Raises an interesting issue.... I have been assuming that cox-2 inhibitors are aspirin without the side effects. I have extremely high regard for aspirin, and I've used TONS of it through years of headaches, despite the warnings of chewing up my gut. Your point is well-taken, and undoubtedly true..... but, aren't we just a tad over-enthusiastic about cox-2 inhibitors? "...The drug (Ridaura) is currently indicated for adults with active rheumatoid arthritis who are not responsive to, or are intolerant of, treatment with non-steroidal anti-inflammatory drugs (NSAIDs)." It would seem like the new Cox-2 inhibitors (Celebrex, Vioxx) might cut into or limit sales of Ridaura. Well, we still get "not responsive to". :-)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next